Biomodulation of Fusion Protein Increases in vitro Cytotoxicity in Cells.(Brief Article)

2000 JUN 15 - (NewsRx.com) --

Ligand Pharmaceuticals Inc. announced the presentation of preclinical study results on May 23, 2000, suggesting that the addition of biomodulatory strategies to the Ontak(R) (denileukin diftitox/DAB389IL-2) treatment regimen may increase the activity of Ontak in patients whose lymphoma cells do not express the interleukin-2 receptor (IL-2R).

The results were presented in New Orleans, Louisiana, at the 36th Annual Meeting of the American Society of Clinical Oncology in a poster session.

Ontak, a targeted cytotoxic biologic from a new class of drugs called fusion proteins, is selectively lethal to IL-2R-expressing …